Etrumadenant - Arcus Biosciences
Alternative Names: A2a/A2b adenosine receptor antagonist - Arcus Biosciences; AB 928; GS-0928Latest Information Update: 09 Jun 2024
At a glance
- Originator Arcus Biosciences
- Developer Arcus Biosciences; Genentech; Gilead Sciences; Memorial Sloan-Kettering Cancer Center; Washington University School of Medicine
- Class Amines; Antineoplastics; Nitriles; Pyridines; Pyrimidines; Small molecules; Triazoles
- Mechanism of Action Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer; Liposarcoma; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer
- Phase I Cancer
- No development reported Bladder cancer; Endometrial cancer; Gastrointestinal cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Oesophageal cancer; Ovarian cancer; Renal cancer; Triple negative breast cancer
- Discontinued Prostate cancer
Most Recent Events
- 02 Jun 2024 Efficacy and adverse events data from the phase Ib/II ARC-9 trial in Colorectal cancer released by Gilead Sciences
- 05 Apr 2024 Interim adverse events and efficacy data from the phase-Ib/II MORPHEUS-PDAC trial in Pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Bladder-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO)